Hospitals and Clinics Segment to Lead Global Newborn Screening Market During 2022–2030

According to our new research study on “Newborn Screening Market Forecast To 2030 – Global Analysis – by Product Type, Technology, Test Type, and End User,” the newborn screening market is expected to grow from US$ 1,206.74 million in 2022 to US$ 2,484.16 million by 2030; it is estimated to record a CAGR of 9.4% from 2022–2030. Key factors driving the newborn screening market growth are the rising burden of congenital diseases, rising funding from government sectors for newborn screening, and the increasing prevalence of newborn disorders.

The newborn screening market, by end user, is segmented into hospitals and clinics, and diagnostic laboratories. The hospitals and clinics segment held a larger share of the market in 2022 and is anticipated to register a higher CAGR in the newborn screening market during the forecast period. Newborn screening is the process by which newborn babies are screened after birth for disorders that may cause severe illness or death without proper detection and intervention. Usually, a healthcare provider performs newborn screening tests in a room or a newborn/nursery area at hospitals. The hospitals and clinics segment is projected to hold a larger share of the newborn screening market in the coming years as these facilities receive maximum patient footfall for newborn baby screening. Better facilities, and the availability of different treatment options and good nursing care under one roof attract patients toward these facilities for different diagnostic and therapeutic procedures. Government schemes, awareness programs, and financial aid attract more patients to visit hospitals and clinics for diagnosis and treatments. Many hospitals and clinics are a vital part of health system development efforts across the world, resulting in a continuous rise in the number of hospitals and clinics every year. They play an important role in offering support to other healthcare providers. The hospital staff are well trained to tackle all emergencies and provide balanced neonatal care.

Asia Pacific is the fastest-growing region of the global newborn screening market in 2022. The projected growth of the market in this region can be associated with the high number of newborn births, the soaring prevalence of congenital diseases, rising awareness regarding early diagnosis of birth defects in newborns, and the presence of organizations working toward offering better solutions for newborn screening.

Screening of newborns in Asia -Pacific is gaining traction; government agencies in China, India, and other countries need to implement newborn screening programs owing to the high birth rate. According to the United Nations International Children's Emergency Fund (UNICEF), 67,385 babies are born in India each day, accounting for one-sixth of childbirths recorded globally in a day. In addition, India has become the most populated nation; as per Worldmapper, ~23 million babies were born in 2022, followed by China with the birth of 10 million babies. With the constantly soaring birth rate, the focus on infant care is increasing in India, as well as in other countries in Asia -Pacific.

According to a study titled “Epidemiology of Congenital Heart Disease in Jinan, China From 2005 to 2020: A Time Trend Analysis,” published in April 2022, the total CHD prevalence was 3.92 per 1,000 births in Jinan. In urban regions, from 2005 to 2020, the prevalence of CHD was 4.81 per 1,000 births compared to 3.17 per 1,000 births in rural areas. The CHD prevalence grew by 157.4% and 316.1% in urban and rural areas, respectively, during 2005–2020.

As per the Department of Health and Aged Care, 300,000 newborn babies are screened every year in Australia. Newborn bloodspot screening programs are delivered at state and territory levels. The Australian government helps fund these programs through the National Health Reform Agreement. Therefore, the above-mentioned factors are likely to play a major role in boosting the growth of the newborn screening market in Asia -Pacific.

Medtronic Plc, LifeCell International Pvt Ltd, Zentech SA, Trivitron Healthcare, PerkinElmer Inc, Waters Corp, Bio-Rad Laboratories Inc, Masimo Corp, Natus Medical Inc, Baebies Inc, and MRC Holland BV are among the leading companies operating in the newborn screening market.

Based on product type, the newborn screening market is segmented into reagents and assay kits and instruments. In terms of technology, the newborn screening market is segmented into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assays, pulse oximetry screening technology, and other technologies. Based on test type, the newborn screening market is segmented into dry blood spot tests, hearing screen tests, critical congenital heart disease tests, and other tests. Based on end user, the newborn screening market is segmented into hospitals and clinics, and diagnostic laboratories. By geography, the newborn screening market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com